SCHEMBL19989734

SCHEMBL19989734

COC(=O)NC[C@H](N)Cc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 5/20 0.65
LAP3 P28838 1/20 0.50
EPHX1 P07099 1/20 0.50
GGT1 P19440 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27791789 1.00 MMP2 (0.65) MMP2LAP3EPHX1GGT1
SCHEMBL28308216 0.87 MMP2 (0.65) MMP2EPHX1GGT1
SCHEMBL3604545 0.85 MMP2 (0.58) MMP2
SCHEMBL2548977 0.85 MMP2 (0.58) MMP2
SCHEMBL2548981 0.85 MMP2 (0.58) MMP2
SCHEMBL5969207 0.84 MMP2 (0.61) MMP2
SCHEMBL5969212 0.84 MMP2 (0.61) MMP2
SCHEMBL5568037 0.83 MMP2 (0.69) MMP2EPHX1GGT1
SCHEMBL218878 0.83 MMP2 (0.73) MMP2EPHX1GGT1
SCHEMBL218877 0.83 MMP2 (0.73) MMP2EPHX1GGT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US disclosed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US disclosed
US-10314808-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2019-06-11 US disclosed
US-20180085337-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085337-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885LAP3 1332/4885EPHX1 3504/4885
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885LAP3 1332/4885EPHX1 3504/4885
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885LAP3 1332/4885EPHX1 3504/4885
US-10314808-B2 Aminocarbonylcarbamate compounds SLC6A3, SLC6A2, SLC6A4 MMP2 2633/4885LAP3 1332/4885EPHX1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.